............................
2015
2014
2013
Archive
............................
Portfolio News
............................
New Leaf News
............................
|
BioRelix Enters Antibacterial
Collaboration with Merck
NEW HAVEN, CONNECTICUT, October 4, 2010 - BioRelix, Inc. today
announced that it has entered into a research collaboration
agreement with a subsidiary of Merck & Co., Inc. to identify new
antibacterial drug candidates.
Under the agreement, BioRelix will apply its proprietary
riboswitch technology platform to identify compounds with
activity against a number of bacterial targets. The parties will
jointly undertake preclinical programs, and Merck will
subsequently be responsible for clinical evaluation of any
candidates chosen for further development. Merck will pay
BioRelix an upfront fee and provide research funding. In
addition, BioRelix is eligible to receive payments upon
achievement of specified milestones associated with advancement
of drug candidates and royalties on the sales of any products
derived from the collaboration.
"There is a tremendous patient need for new agents against
difficult to treat and drug resistant infections," stated Brian
Dixon, Chief Executive Officer of BioRelix. "We’re delighted to
combine our technology with such a capable partner in order to
provide new mechanisms and new chemistry to fight these life
threatening diseases."
"Collaborations with companies like BioRelix are essential as we
seek to apply the latest innovative drug discovery technologies
towards the discovery of new much needed antibacterial
medications," said Roger Pomerantz, MD, senior vice president,
and Global Franchise Head, Infectious Diseases, Merck Research
Laboratories.
|